

Alexa Sengupta

Associate

Nashville
+1.615.780.6768

Alexa.Sengupta@klgates.com

OVERVIEW

Alexa Sengupta is an associate and a member of the Healthcare and FDA practice group. She focuses her practice on both healthcare and FDA regulatory matters, advising both healthcare and life sciences clients on regulatory issues.

Alexa has experience assisting with federal and state healthcare regulatory, operational and compliance matters, including state and federal licensure analysis and changes, fraud and abuse concerns, privacy and telehealth matters as well as other day-to-day operational issues. Alexa also has advised medical device, cosmetic and dietary supplement clients on a variety of regulatory and FDA questions.

Alexa also assists in the execution of a wide array of corporate transactions with healthcare and life sciences clients, by advising clients through the full lifecycle of mergers and acquisitions, strategic collaborations, and joint ventures.

PROFESSIONAL BACKGROUND

Prior to joining the firm, Alexa served as a corporate healthcare associate at a US law firm, where she counseled organizations regarding healthcare regulatory compliance and operational matters and assisted in corporate transactions.

EDUCATION

- J.D., University of Tennessee College of Law, 2019 *(Tennessee Law Review)*
- B.A., Middle Tennessee State University, 2014

THOUGHT LEADERSHIP *POWERED BY HUB*

- 12 October 2023, FDA Issues Guidance on Informed Consent for IRBs, Clinical Investigators, and Sponsors
- 28 June 2023, Litigation Minute: FDA and State Action on PFAS in Food Packaging

- 9 March 2023, MSSP vs ACO REACH: Five Considerations for Legal Counsel
- 5 January 2023, Breakthrough FDA Decision: Agency Completes its First Pre-Market Consultation for Human Food Made From Cultured Animal Cells
- 18 October 2022, FDA Proposes Updates Regulatory Definition of "Healthy" for the First Time Since 1994
- 7 June 2022, The Drive to Align ESG and Health Equity Priorities With Medicare Reimbursement Models
- 16 March 2022, The Next Evolution of ACO Models – Applications for the ACO REACH Model Are Due 22 April 2022

AREAS OF FOCUS

- Healthcare and FDA
- Healthcare Transactions